RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $341.00 price target on Biogen (NASDAQ: BIIB) after attending ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE